Who are Lactobacillus Rhamnosus's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Lactobacillus Fermentum.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/lactobacillus-rhamnosus.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Lactobacillus Rhamnosus — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Lactobacillus Rhamnosus (Lactobacillus Rhamnosus) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Live biotherapeutic / Probiotic. Area: Gastroenterology / Immunology.

marketed Live biotherapeutic / Probiotic Gastroenterology / Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Lactobacillus Rhamnosus (Lactobacillus Rhamnosus) — Chang Gung Memorial Hospital. Lactobacillus rhamnosus is a probiotic bacterium that modulates the gut microbiota and enhances intestinal barrier function and immune tolerance.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Lactobacillus Rhamnosus TARGET	Lactobacillus Rhamnosus	Chang Gung Memorial Hospital	marketed	Live biotherapeutic / Probiotic
Lactobacillus Fermentum	Lactobacillus Fermentum	HEM Pharma Inc.	marketed	Live biotherapeutic / Probiotic

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Live biotherapeutic / Probiotic class)

Chang Gung Memorial Hospital · 1 drug in this class
HEM Pharma Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Lactobacillus Rhamnosus — Competitive Intelligence Brief. https://druglandscape.com/ci/lactobacillus-rhamnosus. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing